b1-, b2-and b3-adrenoceptors determined by functional, binding and reverse transcription polymerase chain reaction (RT-PCR) studies are present in chick astrocytes and activation of b2-or b3-adrenoceptors increase glucose uptake. The aims of the present study are to identify which b-adrenoceptor subtypes are present in mouse astrocytes, the signal transduction mechanisms involved and whether b-adrenoceptor stimulation regulates glucose uptake.
Introduction
Adrenoceptors are G protein-coupled receptors (GPCRs) comprising three types: a1-, a2-and b-adrenoceptors (nomenclature follows Alexander et al., 2009) . a1-Adrenoceptors couple to Gq to activate phospholipase C and increase inositol trisphosphate and diacylglycerol; a2-adrenoceptors couple to Gi to negatively regulate adenylyl cyclase and cAMP levels; whereas b-adrenoceptors couple to Gs to positively regulate adenylyl cyclase to increase intracellular cAMP levels (Alexander et al., 2009) . While b-adrenoceptors primarily couple to Gs, coupling to Gi has also been documented for the b2- (Daaka et al., 1997; Xiao, 2001; Woo et al., 2009 ) and b3-adrenoceptors Sato et al., 2005; . b3a-and b3b-adrenoceptors are splice variants of the b3-adrenoceptor that show identical pharmacological profiles , but the b3a-adrenoceptor couples solely to Gs whereas the b3b-adrenoceptor couples both to Gs and Gi Sato et al., 2005; .
In rodents, b-adrenoceptors are expressed throughout the whole brain (Nicholas et al., 1993) . In many brain regions, b1-and b2-adrenoceptors are expressed at similar densities but b1-adrenoceptors predominate in the cerebellar cortex, hippocampus and basal ganglia (Paschalis et al., 2009 ) whereas b2-adrenoceptors predominate in the cerebellum and thalamus (Rainbow et al., 1984) . b3-Adrenoceptors in the rodent brain are limited to the hippocampus, hypothalamus, amygdala and cerebral cortex (Summers et al., 1995) . b3-Adrenoceptors have roles in the regulation of food intake (Tsujii and Bray, 1998) and for the treatment of anxiety and depressive disorders (Stemmelin et al., 2008) and activation following intraventricular injection of b3-adrenoceptor agonists increases c-fos expression in the hypothalamus (Castillo-Melendez et al., 2000) . The b3a-is the predominant b3-adrenoceptor isoform in adipose tissue, skeletal muscle or gut whereas a larger proportion of b3b-adrenoceptors are found in the brain (hypothalamus and cortex).
Astrocytes are a major glial cell in the brain. Originally thought to just play a structural role, they have now been shown to have fundamental roles in brain function including (but not limited to) metabolism, transmitter reuptake and release, synaptic transmission and memory formation (Gibbs et al., 2008c) . Early studies of rodent astrocytes and glial cells identified b-adrenoceptors (Salm and McCarthy, 1989; Shao and Sutin, 1992 ) but subtype distribution is unclear, with some studies in glial cells indicating either b2-adrenoceptors (Shao and Sutin, 1992) , b1-adrenoceptors (Sapena et al., 1996) or a mixed population of both b1-and b2-adrenoceptors (Voisin et al., 1987; Junker et al., 2002; Mori et al., 2002; Tanaka et al., 2002; Ghosh and Das, 2007) . b-Adrenoceptors have a variety of roles in astrocytes including regulation of cellular morphology (Shain et al., 1987) , protection against glutamate-induced cell death (Junker et al., 2002) and protection against inflammatory mediators (Abdulla and Renton, 2005) . Studies investigating b-adrenoceptor mediated regulation of glucose and glycogen metabolism on mammals are sparse but include b-adrenoceptor-regulation of glycogenolysis (Sorg and Magistretti, 1991; O'Dowd et al., 1995) and b-adrenoceptor-mediated increases in glucose uptake in glial cells (Hsu and Hsu, 1990) . The possibility that b 3-adrenoceptors occur in glial cells has received very little attention; b3-adrenoceptor mRNA was absent in rat cultured microglia (Tanaka et al., 2002) but both b3-adrenoceptor mRNA and protein were present in chick astrocytes .
In chick astrocytes, a role for b-adrenoceptors in glucose uptake has been established with both b2-adrenoceptors and b3-adrenoceptors regulating this process through a Gs-and Gi-dependent pathway, respectively . Glucose metabolism is important for many functions in the brain, including cognition, memory and learning (Messier, 2004) . We have established that glucose and glycogen metabolism are important for memory formation in the day-old chicks (Gibbs and Summers, 2002; Gibbs et al., 2006; 2008c; Hutchinson et al., 2007; , with b2-adrenoceptormediated memory consolidation requiring astrocytic glycogen breakdown and b3-adrenoceptor-mediated memory consolidation requiring astrocytic glucose uptake Gibbs et al., 2008a,b,c) . Although many studies have been conducted using mouse astrocytes there is no information on the presence of b3-adrenoceptors, or the function of the three different b-adrenoceptor subtypes in these cells. The use of selective b-adrenoceptor subtype knockout (KO) mice facilitates the identification of the roles of the different subtypes in astrocytic function. This study characterizes the b-adrenoceptor subtypes present in FVB (FVB/N), b3-adrenoceptor knockout (b3KO), DBA/1 crossed with C57BL/6J (DBA ¥ C57) and b1b2-adrenoceptor knockout (b1b2KO) mouse astrocytes and investigates their coupling mechanisms and involvement in glucose uptake.
Methods

Animals
All animal care, breeding and experimental procedures were approved by the Monash University Animal Ethics Committee. Newborn (day 0-1) FVB, b3KO (Susulic et al., 1995) , DBA ¥ C57 and b1b2KO mice (Rohrer et al., 1999) were used. The b3KO mice were generated on a FVB background and hence comparisons are made with FVB mice. Because the b1b2KO mice were generated on a 129SVJ, C57Bl6/J and DBA/1 background, comparisons are made with DBA ¥ C57 F1 generation mice. Animals were bred and housed at MouseWorks (Monash University, Clayton) and paired breeding carried out to ensure litters were born at similar times (less than 24 h difference).
Mouse primary astrocyte cell culture
Astrocytes were made from the cerebrum of 0-or 1-day-old mice. Pups were separated from their mothers and used within 30 min. Pups were washed carefully in warmed phosphate buffered saline (PBS) (composition in mM: 136.9 NaCl, 2.7 KCl, 10.1 Na2HPO4, 1.8 KH2PO4, pH 7.4) containing 100 IU·mL -1 penicillin and 100 mg·mL -1 streptomycin and then decapitated. Astrocytes were prepared as previously described and cells suspended in Dulbecco's modified Eagle's medium (DMEM) containing 4.5 g·L -1 glucose, 10% fetal bovine serum (FBS), 12.5 mM·L-glutamine, 1 mg·mL -1 amphotericin B, 100 U·mL -1 penicillin and 100 mg·mL -1 streptomycin at 5 mL per brain. Cells were grown in 75 cm 2 flasks at a density of 10 mL per flask (equivalent to two brains per flask) at 37°C in an atmosphere of 95% air : 5% CO2 for 1 week with medium changes twice a week. Cells were then shaken at 40 r.p.m. at 37°C overnight in an orbital mixer incubator to remove microglial cells before washing twice with PBS. Astrocytes were loosened from the bottom of flasks using 10 mM EDTA in PBS for 30 min at 37°C and seeded into plates. Astrocytes were grown for another 7 days at 37°C under 5% CO2, with twice weekly changes of medium.
Whole cell-binding assay using
Astrocytes were cultured in 48-well plates at a density of 2 ¥ 10 4 cells per well for 7 days. All experiments were performed at 37°C in a total volume of 100 mL for 1 h as previously described . For saturation binding experiments, cells were incubated with either
) alone or in the presence of 1 mM (-)-propranolol for the high-affinity binding site or in the presence of 0.1 mM (-)-alprenolol for the low-affinity site to define non-specific binding. [ 3 H]-CGP12177A was used at a concentration of 5-200 pM when examining the high-affinity b1b2-adrenoceptor site and 100-2000 pM for the low-affinity b3-adrenoceptor site. The hydrophilic radioligand [ 3 H]-CGP12177A was used to measure whole cell binding as it labels cell surface receptors (Staehelin et al., 1983) whereas the hydrophobic [
125 I]-cyanopindolol labels both cell surface and internalized receptors and is more suited to radioligand binding experiments performed with cell membrane preparations. While both radioligands exhibit little selectivity for b1-and b2-adrenoceptors, they have a lower affinity for b3-adrenoceptors, as do the antagonists alprenolol and propranolol, with high concentrations of alprenolol typically used to define non-specific binding at b3-adrenoceptors and propranolol typically used to define non-specific binding at b1-and b2-adrenoceptors (Dunigan et al., 2000) .
Competition experiments were performed at the highaffinity site using a range of concentrations of unlabeled drug (b1-adrenoceptor antagonist CGP20712A, b2-adrenoceptor antagonist ICI118551 or b3-adrenoceptor antagonist SR59230A) and 100 pM of [ 3 H]-CGP12177A with non-specific binding defined by 1 mM (-)-propranolol. Reactions were terminated by aspiration and cells washed twice with PBS. Astrocytes were digested (0.2 M NaOH (200 mL), 50°C), the contents of the wells transferred to scintillation vials and radioactivity counted on a b-counter (Tri-Carb 2900TR; PerkinElmer Life and Analytical Sciences, Boston, MA, USA). Wells that were not incubated with radiolabel were used for protein determination (Lowry et al., 1951) using bovine serum albumin (BSA) as the standard.
cAMP accumulation assay
Astrocytes were cultured in 96-well plates at a density of 1 ¥ 10 4 cells·per well for 7 days. Cells were serum-starved overnight before the cAMP assay was carried out as previously described (Sato et al., 2008) . In each experiment, 100 mM forskolin was used as a positive control and all data expressed as % of this response. To investigate the effect of G i, cells were treated with Pertussis toxin (PTX; 100 ng·mL -1 ) 16-20 h prior to stimulation with drugs. In experiments investigating the effects of antagonists or weak Gs coupling of b3-adrenoceptors, cells were treated with 300 nM antagonist or 10 mM forskolin, respectively, added simultaneously with the agonist and incubated for 30 min.
Reverse transcription polymerase chain reaction (RT-PCR)
Astrocytes were cultured for 7 days in six-well plates at a density of 6 ¥ 10 5 cells per well. RNA was extracted using Trizol according to the manufacturer's instructions (Invitrogen Australia, Melbourne, Vic., Australia). RNA was also extracted from brown fat and brain from a 3-week-old male FVB mouse. The yield and quality of RNA was assessed by measurement of absorbance at 260 and 280 nm and by electrophoresis on 1.0% agarose gel. cDNAs were synthesized by RT of 1 mg of each total RNA using oligo(dT15) as previously described (Roberts et al., 1999) .
The PCR amplification cycle number and annealing temperatures for each b-adrenoceptor subtype were: b1-and b3-adrenoceptors 32 cycles at 64°C, b2-adrenoceptor 27 cycles at 60°C, b3-adrenoceptor splice variants 28 cycles at 64°C; performed on cDNA equivalent of 100 ng starting RNA using primers for b1-, b2-or b3-adrenoceptors (Invitrogen; Table 1 ). For all b-adrenoceptor PCR, PCR mixes contained 0.5 U Platinum Pfx DNA polymerase (Invitrogen), 1 ¥ Pfx buffer, 1 ¥ enhancer solution, 130 mM deoxyribonucleotide triphosphates (dNTPs), 1.5 mM MgSO4, 5.8 pmol forward and 5.8 pmol reverse primer. Following amplification, PCR products were separated by electrophoresis on 1.3% agarose gels and images captured digitally.
[ 3 H]-2-deoxy-D-glucose uptake assay
Astrocytes were grown in 24-well plates at a density of 4 ¥ 10 4 cells per well for 7 days. Glucose uptake assays were performed as previously described (Klip et al., 1982; Tanishita et al., 1997) with some modifications. On day 6, medium was changed to serum free media. The following morning, media was replaced with warmed DMEM (4.5 g·L -1 glucose) and drugs added. After incubation, plates were washed twice with warmed PBS and media changed to warmed glucose-free DMEM. Drugs were re-added for 10 min followed by 10 min incubation with [ 3 H]-2-deoxy-D-glucose (50 nM). While 2-deoxyglucose can inhibit glycolysis and thereby possibly produce anaerobic respiration, this occurs at high concentrations (10-50 mM or higher) and used over a long period of time (hours-days) (Woodward and Hudson, 1954; Jain et al., 1985) . Thus, in the current study, we used 50 nM [
3 H]-2-deoxy-D-glucose over 10 min with uptake being linear over this time (data not shown). Reactions were terminated by aspiration and the cells washed twice with PBS. Samples were digested (0.2 M NaOH, 30 min, 50°C), transferred to scintillation vials and radioactivity counted. Cytochalasin B (10 mM) was used to determine non-facilitated glucose uptake (Birnbaum, 1989) .
Analysis of data
Whole cell binding data was analysed using non-linear curve fitting (GraphPad PRISM version 5.0; GraphPad Software Inc., San Diego, CA, USA) using a one-site model to determine KD and Bmax (saturation binding experiments) or non-linear curve fitting for one-site competition experiments to obtain pKi values using the Cheng and Prusoff equation (Cheng and Prusoff, 1973) . A standard curve from cAMP standards (10 -6 M to 10 -11 M) was generated using GraphPad PRISM and points read from standard curve to determine cAMP accumulation. Data was normalized to the forskolin (10 -4 M) response in each respective plate. Statistical significance was determined using two-way analysis of variance (ANOVA) or Student's t-test. P-values < 0.05 were considered significant. Where appropriate, pKB values were calculated using the method of Furchgott (1972) where pKB = log(dose ratio -1) -log[antagonist]. Glucose uptake experiments were performed in triplicate and data were analysed using non-linear curve fitting (GraphPad PRISM version 5.0) to obtain pEC50 values. All results are expressed as mean Ϯ SEM of n experiments. 
Results
Expression of b 1 -, b 2 -and b 3 -adrenoceptor mRNA in mouse astrocytes
RT-PCR was carried out to determine the b-adrenoceptor subtypes that are expressed in mouse astrocytes with brown fat and brain from an FVB mouse used as positive controls, as both these tissues express all three b-adrenoceptor subtypes. b1-and b2-adrenoceptor mRNA were detected in FVB, DBA ¥ C57 and b3KO astrocytes and b3-adrenoceptor mRNA was present in FVB, DBA ¥ C57 and b1b2KO astrocytes ( Figure 1A ). This also confirmed that the b1b2KO and b3KO mice were of the correct genotype. The mouse b3-adrenoceptor gene contains two exons that undergo alternative splicing to produce two splice variants of the mouse b3-adrenoceptor that are expressed, the b3a-adrenoceptor and the b3b-adrenoceptor . Using intron-spanning primers that detect both transcripts, it appears that the b3a-adrenoceptor is the predominant isoform in mouse astrocytes ( Figure 1B) .
[ 3 H]-CGP12177A binding in mouse astrocytes
Receptor binding was used to determine the level of b-adrenoceptor protein expression. A high-affinity b1b2-adrenoceptor site was demonstrated in astrocytes from all mouse strains (FVB pKD 9.57 Ϯ 0.28, Bmax 96.35 Ϯ 30.59 fmol·mg -1 protein, n = 14; b3KO pKD 9.79 Ϯ 0.27, Bmax 89.61 Ϯ 23.09 fmol·mg -1 protein, n = 12; DBA ¥ C57 pKD 9.61 Ϯ 0.17, Bmax 95.8 Ϯ 41.3 fmol·mg -1 protein, n = 5) except b1b2KO astrocytes (Figure 2) , confirming that the high-affinity site reflects b1-or b2-adrenoceptors. Competition for binding at this high-affinity site demonstrated that the selective b1-adrenoceptor antagonist CGP20712A had the highest affinity whereas affinities of the selective b2-adrenoceptor antagonist ICI118551 or the b3-adrenoceptor antagonist SR59230A were much lower (Table 2; Figure 3 ). This suggests that b1-adrenoceptors predominate in mouse astrocytes.
b 3-Adrenoceptor saturation experiments demonstrated a low-affinity binding site in astrocytes from all mouse strains including b3KO mice (FVB pKD 9.12 Ϯ 0.05, Bmax 224.5 Ϯ 105.9 fmol·mg -1 protein, n = 5; b3KO pKD 9.15 Ϯ 0.14, Bmax 303.7 Ϯ 118.7 fmol·mg -1 protein, n = 5; DBA ¥ C57 pKD 9.15 Ϯ 0.02, Bmax 128.8 Ϯ 66.8 fmol·mg -1 protein, n = 3; b1b2KO pKD 9.19 Ϯ 0.32, Bmax 54.5 Ϯ 13.7 fmol·mg -1 protein, n = 3) (Figure 4) . The low-affinity binding site in astrocytes from b3KO mice cannot be due to b3-adrenoceptors since no mRNA was present (Figure 1 ), but could be due to [ 3 H]-CGP12177A binding to a low-affinity state of the b1-adrenoceptor (Konkar et al., 2000) .
Effect of the general b-adrenoceptor agonist isoprenaline, the b 2 -adrenoceptor agonist zinterol and the selective b 3 -adrenoceptor agonist CL316243 on cAMP accumulation in mouse astrocytes
The general b-adrenoceptor agonist isoprenaline increased cAMP accumulation in astrocytes from all mouse strains except b1b2KO mice (pEC50 FVB 8.44 Ϯ 0.4, n = 18; b3KO 8.64 Ϯ 0.4, n = 15; DBA ¥ C57 8.35 Ϯ 0.3, n = 16; b1b2KO not determined, n = 10), suggesting that isoprenaline increases cAMP accumulation by activating b1-or b2-adrenoceptors. Zinterol, a b2-adrenoceptor agonist, increased cAMP accumulation in FVB, b3KO and DBA ¥ C57 mouse astrocytes, but not in b1b2KO astrocytes (pEC50 FVB 7.02 Ϯ 0.4, n = 12; b3KO 7.88 Ϯ 0.5, n = 14; DBA ¥ C57 6.98 Ϯ 0.4, n = 10; b1b2KO not determined, n = 10) suggesting that zinterol increases cAMP accumulation by activating b2-adrenoceptors. The b3-adrenoceptor agonist CL316243 failed to increase cAMP accumulation in astrocytes from any mouse strain at any concentration used (n = 13-17) ( Figure 5 ).
Effect of selective b-adrenoceptor antagonists on cAMP accumulation after stimulation by the general b-adrenoceptor agonist isoprenaline in mouse astrocytes
Concentration response curves to isoprenaline were performed in the absence and presence of selective b-adrenoceptor antagonists (b1-adrenoceptor, CGP20712A; b2-adrenoceptor, ICI118551; b3-adrenoceptor, SR59230A) at a concentration of 300 nM. None of these antagonists alone affected cAMP accumulation (data not shown). CGP20712A antagonized the response to isoprenaline more effectively than ICI118551 or SR59230A in astrocytes from all strains of mice except for b1b2KO mice that failed to show significant cAMP accumulation (Table 3; Figure 6 ). This suggests that b1-adrenoceptors are the predominant adrenoceptor responsible for the isoprenaline-mediated increases in cAMP accumulation.
Effect of CL316243 on cAMP accumulation in mouse astrocytes in the absence and presence of forskolin
To investigate if b3-adrenoceptors were weakly coupled to Gs, forskolin was used to prime cells before the addition of CL316243 (Figure 7) . In FVB astrocytes, CL316243 alone had no significant effect on cAMP accumulation. However when Figure 1 (A) b-Actin, b1-, b2-and b3-adrenoceptor mRNA are expressed in astrocytes isolated from FVB (FVB/N) (Lane 1) and DBA/1 crossed with C57BL/6J (DBA ¥ C57) (Lane 3) mouse strains as well as brain (Lane 5) and brown fat (Lane 6) isolated from an FVB mouse. b3-Adrenoceptor mRNA was not expressed in b3-adrenoceptor knockout astrocytes (Lane 2) and b1-and b2-adrenoceptor mRNA was not expressed in b1b2-adrenoceptor knockout astrocytes (Lane 4). Lane 7 is the negative DNA control. (B) The b3-adrenoceptor splice variants b3a-adrenoceptor (234 bp) and b3b-adrenoceptor (337 bp) are expressed in FVB (Lane 1) and DBA ¥ C57 (Lane 2) mouse astrocytes. The gels shown are representative of at least three experiments performed. AR, adrenoceptor.
Table 2
Binding affinities for b-adrenoceptor ligands at the low-affinity b1b2-adrenoceptor site primed with forskolin, cAMP accumulation increased in a concentration-dependent manner [control pEC50 not determined; +forskolin pEC50 7.83 Ϯ 0.4, max response (maximum cAMP accumulation achieved expressed as a % of the response to forskolin) 175 Ϯ 15, n = 10]. In b3KO astrocytes CL36243 failed to increase cAMP accumulation in the absence or presence of forskolin (n = 10), which suggested that the effect observed in FVB astrocytes was due to b3-adrenoceptors. The DBA ¥ C57 astrocytes showed a similar response to that seen in FVB astrocytes (data not shown). This suggests weak coupling of the b3-adrenoceptor to Gs.
Effect of the G i inhibitor PTX on cAMP accumulation in response to isoprenaline in mouse astrocytes
Mammalian b3-adrenoceptors can couple to both Gs and Gi (Soeder et al., 1999; Hutchinson et al., 2002; Sato et al., 2005) ; therefore, the role of Gi was investigated in mouse astrocytes using PTX (100 ng·mL -1 overnight) to inhibit Gi. FVB astrocytes treated with PTX demonstrated an enhanced response to isoprenaline compared with isoprenaline alone (control pEC50 8.40 Ϯ 0.9, max response (maximum cAMP accumulation achieved expressed as a % of the response to forskolin) 25.7 Ϯ 3.8; +PTX pEC50 8.43 Ϯ 0.6, max response 41.0 Ϯ 4.4; n = 7, *P < 0.05 two-way ANOVA) (Figure 8 ). The b3KO astrocytes showed no significant difference between cells treated with or without PTX (control pEC50 7.93 Ϯ 0.7, max response 20.9 Ϯ 2.4; + PTX pEC50 8.33 Ϯ 0.4, max response 25.5 Ϯ 2.2; n = 4, not significant, two-way ANOVA). DBA ¥ C57 astrocytes showed a similar response to PTX and isoprenaline treatment to FVB astrocytes (data not shown). There was still no observable effect of isoprenaline alone on cAMP accumulation although, after treatment with PTX, high concentrations of isoprenaline appeared to cause cAMP accumulation in b1b2KO astrocytes (data not shown).
Figure 2
Saturation binding of [
3 H]-CGP12177A to a high-affinity site in whole astrocytes isolated from (A) FVB (FVB/N) (n = 14), (B) b3-adrenoceptor knockout (b3KO) (n = 12), (C) DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 5) and (D) b1b2-adrenoceptor knockout (b1b2KO) (n = 3) mice. Incubations were performed for 60 min at 37°C and non-specific binding defined by (-)-propranolol (1 mM). Points show mean Ϯ SEM of experiments performed in duplicate. Results are expressed as specific binding in fmol·mg -1 protein. A high-affinity binding site was present in astrocytes from all mouse strains except for the b1b2KO mice indicating that the majority of receptors are b1-or b2-adrenoceptors at this concentration of [ 3 H]-CGP12177A.
Effect of CL316243 on cAMP accumulation in mouse astrocytes in the absence and presence of forskolin and/or PTX
The coupling of b3-adrenoceptors to Gi was further investigated by constructing concentration-response curves to CL316243 in the absence and presence of forskolin and/or PTX. As previously observed, CL316243 alone did not increase cAMP accumulation either in the presence or absence of PTX. When cells were primed with a submaximal concentration of forskolin, CL316243 was able to increase cAMP accumulation in a concentration-dependent manner, and this effect was enhanced with prior PTX treatment ( Figure 9 ) (+forskolin pEC50 7.17 Ϯ 0.4, max response (maximum cAMP accumulation achieved expressed as a % of the response to forskolin) 224.2 Ϯ 31.5; +forskolin & PTX pEC50 7.56 Ϯ 0.3, max response 282.2 Ϯ 24.2; n = 4, *P < 0.05 two-way ANOVA between CL316243 + forskolin and CL316243 + forskolin and PTX).
Effect of b-adrenoceptor stimulation on glucose uptake in mouse primary astrocytes
Insulin increased glucose uptake in a concentrationdependent manner in all four strains of mouse astrocytes with no significant differences between wild type and respective KO (pEC50 FVB 9.01 Ϯ 0.23, n = 7; b3KO 8.79 Ϯ 0.32, n = 7; DBA ¥ C57 8.99 Ϯ 0.29, n = 8; b1b2KO 9.22 Ϯ 0.31, n = 9) (Figure 10 ). Isoprenaline increased glucose uptake in a concentrationdependent manner in all four strains of mouse astrocytes (pEC50 FVB 8.88 Ϯ 0.3, n = 18; b3KO 8.37 Ϯ 0.4, n = 13; DBA ¥ C57 8.89 Ϯ 0.3, n = 16; b1b2KO 8.71 Ϯ 0.3, n = 14) (Figure 11 ). The b2-adrenoceptor agonist zinterol increased glucose uptake in FVB, b3KO and DBA ¥ C57 astrocytes but this effect was not present in b1b2KO astrocytes (pEC50 FVB 9.58 Ϯ 0.2, n = 18; b3KO 8.99 Ϯ 0.3, n = 13; DBA ¥ C57 9.15 Ϯ 0.3, n = 11; b1b2KO not determined, n = 10). The b3-adrenoceptor agonist
Figure 3
Competition between [ 3 H]-CGP12177A (100 pM) and either CGP20712A (selective b1-adrenoceptor antagonist), ICI118551 (selective b2-adrenoceptor antagonist) and SR59230A (selective b3-adrenoceptor antagonist) for high-affinity binding in whole astrocytes isolated from (A) FVB (FVB/N) (n = 8-9), (B) b3-adrenoceptor knockout (b3KO) (n = 9-10) and (C) DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 5) mice. Incubations were performed at 37°C for 60 min and non-specific binding defined by (-)-propranolol (1 mM). CL316243 increased glucose uptake in all mouse astrocyte strains except b3KO (pEC50 FVB 9.95 Ϯ 0.4, n = 20; b3KO not determined, n = 8; DBA ¥ C57 8.85 Ϯ 0.4, n = 6; b1b2KO 8.65 Ϯ 0.4, n = 9). There was no significant difference in glucose uptake after treatment with isoprenaline or zinterol between FVB and b3KO astrocytes (two-way ANOVA P = 0.89, P = 0.71, respectively). Similar results were observed for DBA ¥ C57 and b1b2KO astrocytes after treatment with isoprenaline and CL316243 (two-way ANOVA P = 0.31, P = 0.50, respectively). This suggests that b2-and b3-adrenoceptors increase glucose uptake in mouse astrocytes although the role of b1-adrenoceptors in this process is yet to be defined.
Discussion
b-Adrenoceptors have been identified on mammalian astrocytes in several studies (Voisin et al., 1987; Salm and McCarthy, 1989; Shao and Sutin, 1992; Junker et al., 2002; Mori et al., 2002; Tanaka et al., 2002; Ghosh and Das, 2007) although the receptor subtype present is generally not well defined apart from responses typically being mediated by the non-selective b-adrenoceptor agonist isoprenaline and blocked by the non-selective b-adrenoceptor antagonist propranolol. Hence in this study we have aimed to identify which b-adrenoceptor subtypes are present in astrocytes using b-adrenoceptor selective KO mice and to verify whether b-adrenoceptor stimulation increases glucose uptake in mammalian astrocytes. Previous studies demonstrated mRNA expression of all three b-adrenoceptor subtypes in chick astrocytes together with b2-and b3-adrenoceptor protein . In the present study, b1-and b2-adrenoceptor mRNA was identified in astrocytes from all mouse strains tested, except b1b2KO; and b3-adrenoceptor mRNA (including b3a-and b3b-adrenoceptor mRNA) in all strains except for b3KO. While b1-and b2-adrenoceptor mRNA have been demonstrated in rat cultured astrocytes (Joardar et al., 2006; Ghosh and Das, 2007) b3-adrenoceptor mRNA has not, even
Figure 4
Saturation binding of [ 3 H]-CGP12177A to low-affinity site in whole astrocytes isolated from (A) FVB (FVB/N) (n = 5), (B) b3-adrenoceptor knockout (b3KO) (n = 5), (C) DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 4) and (D) b1b2-adrenoceptor knockout (b1b2KO) (n = 3) mice. Incubations were performed for 60 min at 37°C and non-specific binding defined by (-)-alprenolol (0.1 mM). Points show mean Ϯ SEM of experiments performed in duplicate. Results expressed as specific binding in fmol·mg -1 protein. A low-affinity site is present in primary astrocytes from all mouse strains.
though it is present in rat (Summers et al., 1995) and mouse brain regions . The mouse b3-adrenoceptor occurs as two splice variants, b3a-adrenoceptor and b3b-adrenoceptor , that share identical pharmacological but different signalling properties Sato et al., 2005; . The b3b-adrenoceptor has higher expression in the brain compared to other tissues but in astrocytes, the present study identified both b3a-and b3b-adrenoceptor, with b3a-adrenoceptor predominating. Radioligand binding studies displayed high-affinity sites in astrocytes from FVB, b3KO and DBA ¥ C57 mice, but not b1b2KO mice. Bmax values (~90 fmol·mg -1 protein) were comparable with studies in rat cultured astrocytes; 20-30 fmol·mg -1 protein from rat cerebra (Joardar et al., 2006) ;~30 fmol·mg -1 protein from rat forebrain (Sapena et al., 1996) ; 10-60 fmol·mg -1 protein in rat astrocytes (Ghosh and Das, 2007) ; 140-210 fmol·mg -1 protein from rat cerebral astrocytes (Das and Paul, 1994) . Competition binding studies showed CGP20712A to have the highest affinity confirming that b1-adrenoceptors predominate (Sapena et al., 1996) whereas b2-adrenoceptors predominate in chick astrocytes . The b2-adrenoceptor antagonist ICI118551 also competed for this site, albeit with an affinity intermediate between that expected for b2-and b1-adrenoceptors, suggesting that a small population of b2-adrenoceptors exist in mouse astrocytes. Saturation binding studies also showed a low-affinity site in all mouse strains including b3KO astrocytes. This is likely to reflect binding of [ 3 H]-CGP12177A to the lowaffinity form of the b1-adrenoceptor (Pak and Fishman, 1996) . This compares well to our study where [ 3 H]-CGP12177A only binds to the low-affinity site in astrocytes derived from b1b2KO mice. b3-adrenoceptors cannot be responsible for the low-affinity site shown in b3KO astrocytes as b3-adrenoceptor mRNA is not present in these cells, however a low-affinity b1-adrenoceptor site may account for our results.
Figure 5
The effect of the b-adrenoceptor agonist isoprenaline, the b2-adrenoceptor agonist zinterol and the selective b3-adrenoceptor agonist CL316243 on cAMP accumulation in (A) FVB (FVB/N), (B) b3-adrenoceptor knockout (b3KO), (C) DBA/1 crossed with C57BL/6J (DBA ¥ C57) and (D) b1b2-adrenoceptor knockout (b1b2KO) astrocytes. Results expressed as a % of response to forskolin (10 -4 M). Each point shows mean Ϯ SEM (n = 10-18).
All three b-adrenoceptor subtypes couple to Gs to activate adenylate cyclase and increase intracellular cAMP levels. The non-selective b-adrenoceptor agonist isoprenaline, increased cAMP accumulation in FVB, b3KO and DBA ¥ C57 astrocytes but not b1b2KO astrocytes, indicating that isoprenaline increases cAMP through b1-or b2-adrenoceptors. Isoprenaline concentration-response curves were strongly antagonized by CGP20712A with pKB values (8.3-8.6 ; Table 3 ) appropriate for antagonism at b1-adrenoceptors and not b2-or b3-adrenoceptors where pKB values are significantly lower (Table 4 ). The b2-adrenoceptor antagonist ICI118551 weakly antagonized the isoprenaline response Table 3) , with a pKB value lower than its known value for b2-adrenoceptor mediated responses (Table 4 ). SR59230A, first described as a b3-adrenoceptor antagonist , antagonized isoprenaline responses with pKB values of 7.4-7.5 (Table 3) , lower than expected for b3-adrenoceptors that may reflect b1-adrenoceptor antagonist actions (Table 4) Hutchinson et al., 2001 ). However, in other studies SR59230A (<1 mM) did not affect salbutamol (b2-adrenoceptor) or dobutamine (b1-adrenoceptor) mediated cAMP accumulation in rat cerebellum or frontal cortex and failed to antagonize noradrenaline-mediated cAMP generation in brown preadipocytes (predominately b1-adrenoceptor), but did abolish noradrenaline-mediated effects in mature brown adipocytes (predominately b3-adrenoceptor) . Because pKB values for SR59230A were similar in FVB and b3-adrenoceptor KO astrocytes it is likely that SR59230A antagonizes isoprenalinemediated cAMP accumulation in these cells by blocking b1-adrenoceptors. Thus, b1-adrenoceptors play a greater role than b2-or b3-adrenoceptors in isoprenaline-mediated cAMP accumulation in mouse astrocytes. Antagonist pKB values did not differ between FVB and b3KO astrocytes (pEC50 values
Figure 6
Effect of the selective b1-adrenoceptor antagonist CGP20712A, the selective b2-adrenoceptor antagonist ICI118551 and the selective b3-adrenoceptor antagonist SR59230A in (A) FVB (FVB/N) (n = 7), (B) b3-adrenoceptor knockout (b3KO) (n = 7), (C) DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 7) and (D) b1b2-adrenoceptor knockout (b1b2KO) (n = 9) mouse primary astrocytes on cAMP accumulation in response to isoprenaline. Concentrations of antagonist used were 300 nM. Results expressed as a percentage of forskolin (10 -4 M). Each point shows mean Ϯ SEM.
Table 4
Affinity values for b-adrenoceptor antagonists at the b1-, b2-or b3-adrenoceptor Antagonist b1-Adrenoceptor b2-Adrenoceptor b3-Adrenoceptor
Figure 7
Effect of the selective b3-adrenoceptor agonist CL316243 and CL316243 in the presence of forskolin (10 mM) on cAMP accumulation in astrocytes from (A) FVB (FVB/N) (n = 10) and (B) b3-adrenoceptor knockout (b3KO) (n = 10). Results expressed as a percentage of forskolin (10 -4 M). Each point shows mean Ϯ SEM. Note that in astrocytes containing b3-adrenoceptors, the response to CL316243 is enhanced in the presence of forskolin.
Figure 8
Effect of isoprenaline and isoprenaline + Pertussis toxin (PTX; 100 ng·mL -1 overnight) on cAMP accumulation in (A) FVB (FVB/N) (n = 7) and (B) b3-adrenoceptor knockout (b3KO) (n = 4) mouse astrocytes. Results expressed as a percentage of forskolin (10 -4 M). Each point shows mean Ϯ SEM.
for isoprenaline were also similar) suggesting that b1-adrenoceptors do not compensate for b3-adrenoceptors as in ileum from b3-adrenoceptor KO mice where b1-adrenoceptor mRNA and protein levels are elevated . Conversely, in brown adipocytes from b3-adrenoceptor KO mice, b1-and a1-adrenoceptors functionally compensate for b3-adrenoceptors without altering mRNA or protein levels (Chernogubova et al., 2005) . We however saw no compensation in b3KO astrocytes by b1-or b2-adrenoceptors based on mRNA, protein or functional results.
The b2-adrenoceptor agonist zinterol increased cAMP levels in a concentration-dependent manner in FVB, b3KO and DBA ¥ C57 astrocytes but not b1b2KO astrocytes, indicating that zinterol increases cAMP through b1-or b2-adrenoceptors. This is likely to be due to b2-adrenoceptor stimulation since responses were abolished in b1b2KO astrocytes and only one previous study has shown zinterol to act at b1-adrenoceptors and increase glucose uptake and cAMP levels in brown adipocytes derived from b3-adrenoceptor KO mice, where b1-adrenoceptors functionally compensate for lack of b3-adrenoceptors (Hutchinson et al., 2006) . Zinterol can also act as a b3-adrenoceptor agonist in some circumstances (Hutchinson et al., 2006) although this is not likely here since responses were identical in FVB versus b3KO astrocytes. This suggests, along with the radioligand binding results, a small population of functional b2-adrenoceptors in mouse astrocytes.
The b3-adrenoceptor agonist CL316243 alone was unable to stimulate cAMP accumulation in any of the mouse astrocytes strains used, indicating that b3-adrenoceptors may not couple strongly enough to Gs in this system to elicit a cAMP response. b3-Adrenoceptors can also couple to Gi in several systems (Chaudhry et al., 1994; Soeder et al., 1999; Hutchinson et al., 2002; Sato et al., 2005; . Our results show that b3-adrenoceptors in mouse astrocytes can weakly couple to Gs and Gi based on two different types of experiments. To investigate if b3-adrenoceptors were Gi coupled, astrocytes were pretreated with the Gi inhibitor PTX before stimulation with isoprenaline. The FVB astrocytes treated with PTX demonstrated an enhanced cAMP response to isoprenaline whereas PTX had no effect on the isoprenaline mediated cAMP response in b3KO astrocytes indicating that b3-adrenoceptors are coupled to Gi. To investigate if b3-adrenoceptors can couple weakly to Gs, astrocytes were treated with CL316243 in the absence and presence of forskolin, a direct adenylate cyclase stimulator. In FVB mouse astrocytes, CL316243 had no effect on its own but when primed with forskolin, cAMP accumulation increased in a concentration dependent manner (pEC50 8.5 Ϯ 0.1). This pEC50 value compares well to other studies in cells and tissues expressing moderate-high levels of b3-adrenoceptors Chernogubova et al., 2005) and suggests that b3-adrenoceptors are weakly coupled to Gs. CL316243 had no effect on cAMP accumulation in b3KO mouse astrocytes in the absence or presence of forskolin, confirming this effect is dependent upon the presence of the b3-adrenoceptor. Assays for cAMP revealed an increased response to CL316243 in the presence of forskolin in b1b2KO astrocytes as compared to
Figure 9
Effect of the selective b3-adrenoceptor agonist CL316243, CL316243 in the presence of forskolin (10 mM 
Figure 10
Effect of insulin on [ 3 H] 2-deoxy-D-glucose uptake in whole astrocytes from (A) FVB (FVB/N) (n = 21), b3-adrenoceptor knockout (b3KO) (n = 7), (B) DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 8) and b1b2-adrenoceptor knockout (b1b2KO) (n = 9) mice. Results expressed as a percentage of basal and normalized to 100% in each experiment. Each point shows mean Ϯ SEM.
Figure 11
The effect of (A, B) isoprenaline (C, D) zinterol or (E, F) CL316243 on [ 3 H]2-deoxy-D-glucose uptake in whole astrocytes from FVB (FVB/N) (n = 18-20) and b3-adrenoceptor knockout (b3KO) (n = 8-13) (A, C, E), and DBA/1 crossed with C57BL/6J (DBA ¥ C57) (n = 6-16) and b1b2-adrenoceptor knockout (b1b2KO) (n = 9-14) (B, D, F) mice. Results are expressed as a percentage of the basal response normalized to 100% in each experiment. Each point shows mean Ϯ SEM. Note there was no glucose uptake after treatment with zinterol in the b1b2KO astrocytes and no glucose uptake after treatment with CL316243 in b3KO astrocytes.
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DBA ¥ C57 astrocytes which may indicate a 'supranormal' response to b3-adrenoceptor agonists as observed by (Rohrer et al., 1999) . In b1b2KO mice there is a supranormal response to CL316243 in cardiac tissues, which may be due to upregulation of vascular b3-adrenoceptors in these mice (Rohrer et al., 1999) .
Glucose uptake is stimulated by b2-adrenoceptors in skeletal muscle and by b3-adrenoceptors in brown adipocytes (Chernogubova et al., 2005) . bAdrenoceptors increase glucose uptake in chick astrocytes Gibbs et al., 2008c) , and in rat astrocyte-enriched cultures (Hsu and Hsu, 1990 ). Here we demonstrated that isoprenaline, zinterol and CL316243 all increased glucose uptake in wildtype mouse astrocytes. The zinterol effect was abolished in b1b2KO astrocytes indicating that it probably acted via b2-adrenoceptors. The effect cannot be due to actions at b3-adrenoceptors (Hutchinson et al., 2006) because zinterol responses were intact in b3KO astrocytes. Additionally CL316243 increased glucose uptake in all astrocyte strains except b3-KO astrocytes, indicating that b3-adrenoceptors can also increase glucose uptake. Glucose uptake can follow activation of different intracellular signalling mechanisms on b-adrenoceptor stimulation (Chernogubova et al., 2005; Nevzorova et al., 2006; Hutchinson et al., 2007) which may or not involve coupling to Gs. In chick astrocytes, both b2-and b3-adrenoceptors increase glucose uptake with b2-adrenoceptors increasing glucose uptake over longer periods of time (due to glycogen depletion) through a Gs-mediated mechanism, whereas b3-adrenoceptors increase glucose uptake rapidly through a Gi-mediated mechanism . However, the mechanism involved in b-adrenoceptor stimulation of glucose uptake in mouse astrocytes has not been examined here in this study and needs further investigation.
A limitation of the present study is the use of whole cerebrum because astrocytes from different brain regions can be morphologically distinct (Pinto et al., 2000) , and express varying levels of transporters, receptors and signal transduction molecules (Hansson, 1988) , including the b1-and b2-adrenoceptors (Ernsberger et al., 1990) . Activation of b-adrenoceptors may therefore involve different signalling pathways depending upon signalling molecules expressed in astrocytes from different brain regions, thus exhibiting region-specific coupling as described for other receptors (Bianco et al., 2009) .
This study identified all b-adrenoceptor mRNA subtypes, including b3-adrenoceptor splice variants, in wildtype mouse astrocytes. b1-Adrenoceptors are the predominant subtype responsible for the cAMP response with a minor b2-adrenoceptor component. b3-Adrenoceptors are coupled to Gi and weakly to Gs whereas b1-and b2-adrenoceptors only couple to Gs. This study demonstrates that all badrenoceptors are involved in glucose uptake although further investigation is required into the signalling mechanisms involved.
